VIR vs. RLAY, BEAM, ALLO, TWST, FATE, HALO, CRSP, KRYS, IBRX, and IMVT
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Relay Therapeutics (RLAY), Beam Therapeutics (BEAM), Allogene Therapeutics (ALLO), Twist Bioscience (TWST), Fate Therapeutics (FATE), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), and Immunovant (IMVT). These companies are all part of the "biological products, except diagnostic" industry.
Relay Therapeutics (NASDAQ:RLAY) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
In the previous week, Vir Biotechnology had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 8 mentions for Vir Biotechnology and 6 mentions for Relay Therapeutics. Vir Biotechnology's average media sentiment score of 1.22 beat Relay Therapeutics' score of 0.50 indicating that Relay Therapeutics is being referred to more favorably in the media.
Vir Biotechnology has a net margin of -677.69% compared to Vir Biotechnology's net margin of -1,263.49%. Relay Therapeutics' return on equity of -32.58% beat Vir Biotechnology's return on equity.
Vir Biotechnology received 1 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 60.94% of users gave Relay Therapeutics an outperform vote while only 48.78% of users gave Vir Biotechnology an outperform vote.
Relay Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relay Therapeutics presently has a consensus price target of $22.20, indicating a potential upside of 246.33%. Vir Biotechnology has a consensus price target of $33.57, indicating a potential upside of 226.89%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Vir Biotechnology.
97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 4.3% of Relay Therapeutics shares are owned by insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Relay Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
Summary
Relay Therapeutics beats Vir Biotechnology on 11 of the 18 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
